A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2018
This article has no abstract
Epistemonikos ID: fc5ae303b9e2628b0d3541c813852a19889f6675
First added on: Apr 11, 2025